Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ozenoxacin→

Ozenoxacin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
245765-41-7
Molecular formula
C21H21N3O3
Molecular weight
363.4 g/mol
Drug class
Non-fluorinated quinolone antibacterialtopical DNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and repair, producing bactericidal activity against susceptible skin pathogens including Staphylococcus aureus and Streptococcus pyogenes.
Indications / reported uses
  • Topical treatment of impetigo due to susceptible Staphylococcus aureus or Streptococcus pyogenes in adults and paediatric patients aged 2 months and older under the US product indication

Sources: US DailyMed — XEPI (ozenoxacin) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ozenoxacin Environmental Risk Assessment (ERA) (the Ozenoxacin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.